---
document_datetime: 2026-02-17 12:34:23
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/uplizna-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: uplizna-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 17.4684652
conversion_datetime: 2026-02-21 12:43:04.88257
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Uplizna

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------------------------------------|----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type II / EMA/VR/0000257358 | This was an application for a group of variations. | 11/12/2025                          | 10/02/2026                                  | SmPC, Annex II, Labelling        |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| C.I.6 Change(s) to therapeutic indication(s) - C.I.6.a Addition of a new therapeutic indication or modification of an approved one - Accepted A. ADMINISTRATIVE CHANGES - A.6 Change in ATC Code / ATC Vet Code - Accepted A grouped application consisting of: C.I.6 (Extension of indication): Extension of indication to include add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) for Uplizna, based on primary analysis results from Study MINT (VIB0551.P3.S1); this is a pivotal phase 3 multicentre, randomised, double-blind, placebo- controlled, parallel-cohort study to evaluate the efficacy and safety of inebilizumab in adults subjects with myasthenia gravis. As a consequence, sections 4.1, 4.2, 4.4 ,4.5, 4.6, 4.8, 5.1, 5.2, and 7 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.2 of the RMP has also been endorsed. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.4. A.6: Update of the ATC code of inebilizumab to   | and PL   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| L04AG10 in line with the 2024 ATC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | INDEX.   |

<div style=\"page-break-after: always\"></div>

| Variation type IA_IN / EMA/VR/0000268735                | B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted   | 13/05/2025   | 10/02/2026   | Annex II and PL        |
|---------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|
| Marketing Authorisation Transfer - H / EMA/T/0000244828 | Transfer of Marketing Authorisation from Horizon Therapeutics Ireland DAC to Amgen Europe B.V                                                                         | 28/01/2025   | 07/03/2025   | SmPC, Labelling and PL |